G49N Stock Overview
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
GenSight Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.37 |
| 52 Week High | €0.92 |
| 52 Week Low | €0.33 |
| Beta | 2.14 |
| 1 Month Change | -9.07% |
| 3 Month Change | -3.68% |
| 1 Year Change | -84.94% |
| 3 Year Change | -95.99% |
| 5 Year Change | -79.62% |
| Change since IPO | -95.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| G49N | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -3.1% | 1.8% |
| 1Y | -84.9% | -22.4% | 2.2% |
Price Volatility
| G49N volatility | |
|---|---|
| G49N Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Volatility Over Time: G49N's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 16 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
| G49N fundamental statistics | |
|---|---|
| Market cap | €32.30m |
| Earnings (TTM) | -€26.22m |
| Revenue (TTM) | €2.96m |
10.9x
P/S Ratio-1.2x
P/E RatioIs G49N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G49N income statement (TTM) | |
|---|---|
| Revenue | €2.96m |
| Cost of Revenue | €0 |
| Gross Profit | €2.96m |
| Other Expenses | €29.18m |
| Earnings | -€26.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 23, 2024
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 100.00% |
| Net Profit Margin | -884.62% |
| Debt/Equity Ratio | -70.7% |
How did G49N perform over the long term?
See historical performance and comparison